You just read:

Viking Therapeutics Presents New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The International Liver Congress™ 2019

News provided by

Viking Therapeutics, Inc.

Apr 11, 2019, 07:02 ET